Bibliographic Details
| Title: |
Linezolid Population Pharmacokinetic Model in Plasma and Cerebrospinal Fluid Among Patients With Tuberculosis Meningitis. |
| Authors: |
Abdelgawad, Noha, Wasserman, Sean, Abdelwahab, Mahmoud Tareq, Davis, Angharad, Stek, Cari, Wiesner, Lubbe, Black, John, Meintjes, Graeme, Wilkinson, Robert J, Denti, Paolo |
| Source: |
Journal of Infectious Diseases; 4/15/2024, Vol. 229 Issue 4, p1200-1208, 9p |
| Subject Terms: |
LINEZOLID, CEREBROSPINAL fluid, CLINICAL trial registries, TUBERCULOSIS patients, TUBERCULOUS meningitis |
| Abstract: |
Background Linezolid is evaluated in novel treatment regimens for tuberculous meningitis (TBM). Linezolid pharmacokinetics have not been characterized in this population, particularly in cerebrospinal fluid (CSF), as well as, following its co-administration with high-dose rifampicin. We aimed to characterize linezolid plasma and CSF pharmacokinetics in adults with TBM. Methods In the LASER-TBM pharmacokinetic substudy, the intervention groups received high-dose rifampicin (35 mg/kg) plus 1200 mg/day of linezolid for 28 days, which was then reduced to 600 mg/day. Plasma sampling was done on day 3 (intensive) and day 28 (sparse). A lumbar CSF sample was obtained on both visits. Results Thirty participants contributed 247 plasma and 28 CSF observations. Their median age and weight were 40 years (range, 27–56) and 58 kg (range, 30–96). Plasma pharmacokinetics was described by a 1-compartment model with first-order absorption and saturable elimination. Maximal clearance was 7.25 L/h, and the Michaelis-Menten constant was 27.2 mg/L. Rifampicin cotreatment duration did not affect linezolid pharmacokinetics. CSF-plasma partitioning correlated with CSF total protein up to 1.2 g/L, where the partition coefficient reached a maximal value of 37%. The plasma-CSF equilibration half-life was ∼3.5 hours. Conclusions Linezolid was readily detected in CSF despite high-dose rifampicin coadministration. These findings support continued clinical evaluation of linezolid plus high-dose rifampicin for the treatment of TBM in adults. Clinical Trials Registration. ClinicalTrials.gov (NCT03927313). [ABSTRACT FROM AUTHOR] |
|
Copyright of Journal of Infectious Diseases is the property of Oxford University Press / USA and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.) |
| Database: |
Complementary Index |
